What is Johnson & Johnson's other oncology — percent change (as a percent)?

Johnson & Johnson (JNJ) reported other oncology — percent change (as a percent) of -10.6% in Q1 2026.

How has Johnson & Johnson's other oncology — percent change (as a percent) changed year-over-year?

Johnson & Johnson's other oncology — percent change (as a percent) decreased by 148.8% year-over-year, from 21.7% to -10.6%.

What is the long-term trend for Johnson & Johnson's other oncology — percent change (as a percent)?

Over 3 years (2021 to 2025), Johnson & Johnson's other oncology — percent change (as a percent) has grown at a -20.0% compound annual growth rate (CAGR), from -92.8% to 47.6%.

What does other oncology — percent change (as a percent) mean?

The percentage growth rate of net sales for the secondary oncology product category compared to the previous period.

Products & Services · Percent Change (as a percent)

Other Oncology — Percent Change (as a percent)

Johnson & Johnson Other Oncology — Percent Change (as a percent) decreased by 335.6% to -10.6% in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 148.8%, from 21.7% to -10.6%. Over 3 years (FY 2021 to FY 2025), Other Oncology — Percent Change (as a percent) shows an upward trend with a -20.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementSegment

CategoryGrowth

SignalHigher is better

VolatilityVolatile

First reportedQ1 2018

Last reportedQ1 2026Apr 22, 2026

How to read this metric

A positive percentage indicates accelerating demand or successful commercial execution, whereas a negative percentage suggests slowing market adoption or competitive pressure.

Detailed definition

This metric measures the period-over-period percentage growth or decline in net sales for the 'Other Oncology' product c...

Peer comparison

Comparable to year-over-year or sequential revenue growth rates for specific therapeutic sub-segments reported by other large-cap biopharmaceutical companies.

Metric ID: jnj_segment_other_oncology_percent_change_as_a_percent

Historical Data

19 periods

	Q2 '21	Q3 '21	Q4 '21	Q1 '22	Q2 '22	Q3 '22	Q4 '22	Q1 '23	Q2 '23	Q3 '23	Q1 '24	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Value	-40.9%	-37.6%	-0.1%	-35.1%	7.5%	23.1%	-17%	37.4%	27.8%	34.5%	80.2%	84.2%	24.8%	-96.8%	21.7%	11.7%	9.7%	4.5%	-10.6%
QoQ Change	—	+8.1%	+99.7%	<-999%	+121.4%	+208.0%	-173.6%	+320.0%	-25.7%	+24.1%	+132.5%	+5.0%	-70.5%	-490.3%	+122.4%	-46.1%	-17.1%	-53.6%	-335.6%
YoY Change	—	—	—	—	+118.3%	+161.4%	<-999%	+206.6%	+270.7%	+49.4%	+114.4%	+202.9%	-28.1%	—	-72.9%	-86.1%	-60.9%	+104.6%	-148.8%

Range-96.8% – 84.2%

CAGR-25.9%

Avg YoY Growth<-999%

Median YoY Growth+77.0%

Current Streak4 quarters decline

Similar Metrics at Other Companies

Natera, Inc.NTRA View metric

McKessonMCK View metric

Kimberly-ClarkKMB View metric

ROP

Roper Technologies, Inc.ROP View metric

Natera, Inc.NTRA View metric

Frequently Asked Questions

What is Johnson & Johnson's other oncology — percent change (as a percent)?: Johnson & Johnson (JNJ) reported other oncology — percent change (as a percent) of -10.6% in Q1 2026.
How has Johnson & Johnson's other oncology — percent change (as a percent) changed year-over-year?: Johnson & Johnson's other oncology — percent change (as a percent) decreased by 148.8% year-over-year, from 21.7% to -10.6%.
What is the long-term trend for Johnson & Johnson's other oncology — percent change (as a percent)?: Over 3 years (2021 to 2025), Johnson & Johnson's other oncology — percent change (as a percent) has grown at a -20.0% compound annual growth rate (CAGR), from -92.8% to 47.6%.
What does other oncology — percent change (as a percent) mean?: The percentage growth rate of net sales for the secondary oncology product category compared to the previous period.